CLINICAL TRIAL EVIDENCE FOR DUAL GLP-1/GLUCAGON RAs AND TRIPLE AGONISTS IN MASH Survodutide Survodutide, a weekly dual GLP-1/GCG agonist, was assessed in a phase 2 dose-finding trial (NCT04771273) including 293 individuals with histologically confirmed MASH and fibrosis stages F1-F3 [46]
03 research advantages Retatrutide represents the next generation of metabolic research molecules
PubMed Raun K, et al
Injection-site reactions are very common
CagriSema is cagrilintide + semaglutide , a fixed-dose once-weekly combination developed by Novo Nordisk and studied in the REDEFINE program ( REDEFINE 1, NCT05567796 )
10.1016/j.mri.2019.10.004 Summary Keywords magnetic resonance spectroscopy, glutathione, metalloproteinase (MMP), myeloperoxidase (MPO), psychiatric disorder, posttraumatic stress disorder (PTSD) Citation Watling SE, Rhind SG, Warsh J, Green D, McCluskey T, Tong J, Truong P, Chavez S, Richardson JD, Kish SJ and Boileau I (2023) Exploring brain glutathione and peripheral blood markers in posttraumatic stress disorder: a combined [1H]MRS and peripheral blood study
